Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
June 27 2018 - 8:00AM
Galectin Therapeutics, Inc. (NASDAQ:GALT),
the leading developer of therapeutics that target galectin proteins
to treat fibrosis and cancer, today announced that the Company has
received notice of issuance of U.S. Patent Number
9,968,631 titled "Method and Treatment of Pulmonary
Fibrosis.” The patent's principal claims cover method of use of
GR-MD-02 as a means to treat pulmonary fibrosis. The patent is
expected to provide broad protection for the use of GR-MD-02 for
compositions, methods of using and methods of manufacturing
compositions capable of treating pulmonary fibrosis. The patent
coverage extends to 2032.
The patent includes a method in obtaining a composition for
parenteral or enteral administration comprising a
galacto-rhamnogalacturonate in a pharmaceutical acceptable carrier
and administering to a subject in need of an effective dose of the
composition that results in at least five percent improvement of
pulmonary function tests where the subject has at least a primary
or secondary lung fibrotic disease. The Company’s GR-MD-02 compound
is covered by this patent.
"This patent protects our commercial ability to use GR-MD-02 to
potentially treat pulmonary fibrosis and is yet another example of
the widespread applicability of our galectin-3 inhibitor in
treating fibrotic disease," said Dr. Harold H. Shlevin, chief
executive officer of Galectin Therapeutics. "Pharmaceutical
companies may have an interest in this disease as there is a
sizeable section of the population in need of treatment and well
defined regulatory pathways for approval of agents to treat
pulmonary fibrosis. This patent further strengthens the protection
of the intellectual property behind our proprietary compound,
GR-MD-02, which has been shown in animal models to resolve fibrosis
in a variety of tissues and organs. The company is currently
focused on planning and conducting additional supportive work to
prepare for a Phase 3 trial for GR-MD-02 in NASH cirrhosis based on
the positive effects of GR-MD-02 on HVPG and the possible
prevention or postponement of development of esophageal varices in
its Phase 2 NASH-CX trial, which we believe is the first large,
randomized clinical trial of any drug to demonstrate a clinically
meaningful improvement in these patients.”
About Galectin Therapeutics
Galectin Therapeutics is developing promising therapies for the
treatment of fibrotic liver disease, and cancer based on the
Company's unique understanding of galectin proteins, which are key
mediators of biologic function. Galectin seeks to leverage
extensive scientific and development expertise as well as
established relationships with external sources to achieve
cost-effective and efficient development. The Company is pursuing a
development pathway to clinical enhancement and commercialization
for its lead compounds in liver fibrosis and cancer. Additional
information is available at www.galectintherapeutics.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements relate to future events or future financial
performance, and use words such as “may,” “estimate,” “could,”
“expect” and others. They are based on management’s current
expectations and are subject to factors and uncertainties that
could cause actual results to differ materially from those
described in the statements. These statements include those
regarding the hope that Galectin’s development program for GR-MD-02
will lead to the first therapy for the treatment of fatty liver
disease with cirrhosis and those regarding the hope that our lead
compounds will be successful in connection with cancer
immunotherapy and in other fibrotic disease including amongst
others in pulmonary fibrosis. Factors that could cause actual
performance to differ materially from those discussed in the
forward-looking statements include, among others, that Galectin may
not be successful in developing effective treatments and/or
obtaining the requisite approvals for the use of GR-MD-02 or any of
its other drugs in development; the Company’s current clinical
trial and any future clinical studies may not produce positive
results in a timely fashion, if at all, and could prove time
consuming and costly; plans regarding development, approval and
marketing of any of Galectin’s drugs are subject to change at any
time based on the changing needs of the Company as determined by
management and regulatory agencies; regardless of the results of
any of its development programs, Galectin may be unsuccessful in
developing partnerships with other companies or raising additional
capital that would allow it to further develop and/or fund any
studies or trials. Galectin has incurred operating losses
since inception, and its ability to successfully develop and market
drugs may be impacted by its ability to manage costs and finance
continuing operations. For a discussion of additional factors
impacting Galectin’s business, see the Company’s Annual Report on
Form 10-K for the year ended December 31, 2017, and subsequent
filings with the SEC. You should not place undue reliance on
forward-looking statements. Although subsequent events may cause
its views to change, management disclaims any obligation to update
forward-looking statements.
Galectin Therapeutics and its associated logo is a
registered trademark of Galectin Therapeutics Inc.
Contact:
Galectin Therapeutics, Inc. Jack Callicutt, Chief Financial
Officer 678-620-3186 ir@galectintherapeutics.com
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Apr 2024 to May 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From May 2023 to May 2024